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Chronic inflammation has been implicated in the development of epithelial ovarian cancer (EOC); 
yet, the contribution of inflammatory foods and nutrients to EOC risk has been understudied. We 
investigated the association between the dietary inflammatory index (DII), a novel literature-
derived tool to assess the inflammatory potential of one’s diet, and EOC risk in African American 
(AA) women in the African American Cancer Epidemiology Study (AACES), the largest 
population-based case-control study of EOC in AA women to date. The energy-adjusted DII (E-
DII) was computed per 1,000 kilocalories from dietary intake data collected through a food 
frequency questionnaire, which measured usual dietary intake in the year prior to diagnosis for 
cases or interview for controls. Adjusted odds ratios (OR) and 95% confidence intervals (CI) were 
estimated using multivariable logistic regression for the association between the E-DII and EOC 
risk. 493 cases and 662 controls were included in the analyses. We observed a 10% increase in 
EOC risk per a one-unit change in the E-DII (OR=1.10, 95% CI=1.03–1.17). Similarly, women 
consuming the most pro-inflammatory diet had a statistically significant increased EOC risk in 
comparison to the most anti-inflammatory diet (ORQuartile4/Quartile1=1.72; 95% CI=1.18–2.51). We 
also observed effect modification by age (p<0.05), where a strong, significant association between 
the E-DII and EOC risk was observed among women older than 60 years, but no association was 
observed in women aged 60 years or younger. Our findings suggest that a more pro-inflammatory 
diet was associated with an increased EOC risk, especially among women older than 60 years.
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INTRODUCTION
In a seminal paper by Ness and Cottreau1, chronic inflammation was implicated as an 
underlying mechanism contributing to ovarian carcinogenesis. Inflammation can influence 
tumor development through stimulation of DNA damage, increased cell division that can 
give rise to DNA repair aberrations, promotion of angiogenesis, and facilitation of 
invasion.1,2 Several studies report an association between biological markers of 
inflammation, such as C-reactive protein (CRP) and circulating interleukins, and ovarian 
cancer risk.3–5 Additionally, an increased risk of ovarian cancer has been observed for 
several factors that enhance inflammation (e.g., body powder applied to genital areas, 
endometriosis, and pelvic inflammatory disease)6–9 and an inverse association has been 
observed for anti-inflammatory factors (e.g., aspirin, nonsteroidal anti-inflammatory 
drugs).10,11 Dietary habits also can contribute to chronic inflammation; traditional 
Mediterranean diets (high intake of fruits, vegetables, and whole-grains) have been 
associated with lower levels of inflammation in comparison to Western diets (high intake of 
red meat and simple carbohydrates).12 Yet, the impact of an inflammatory diet on the risk of 
ovarian cancer has been understudied.
Cavicchia and colleagues13 developed a novel literature-derived tool to assess the 
inflammatory potential of one’s diet, the dietary inflammatory index (DII). Since then, the 
DII was updated by Shivappa, et al.14 to reflect the literature on diet and inflammation 
through 2010. The improved DII has been validated by examining its relationship to 
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inflammatory biomarkers (e.g., CRP and interleukin-6).15–18 Additionally, a more pro-
inflammatory diet, as defined by higher DII scores, has been linked to an increased risk of 
several cancers, including colorectal19,20, pancreatic21, prostate22, breast23, and endometrial 
cancer.24 Specific to ovarian cancer, a recent study25 observed an increased risk among 
Italian women who consumed a more pro-inflammatory diet. However, as that study was 
conducted among Italian women, the results may not be generalizable to other, non-White 
populations. Dietary patterns in Italy tend to be healthier than those in the United States26 
and there are considerable differences in inflammation by race among the general 
population, with higher levels of inflammatory biomarkers present among African 
Americans (AA) compared to Whites.27–29 In this study, we will use the largest case-control 
study of epithelial ovarian cancer (EOC) in AA women, the African American Cancer 
Epidemiology Study, to examine the association between the DII and EOC risk among AA 
women in the United States. We hypothesize that AA women consuming a more pro-
inflammatory diet will have an increased risk of EOC.
MATERIALS AND METHODS
Study Population
The African American Cancer Epidemiology Study (AACES) is an ongoing, population-
based case-control study of invasive epithelial ovarian cancer in AA women across eleven 
geographic locations in the United States, including Alabama, Georgia, Illinois, Louisiana, 
Michigan, North Carolina, New Jersey, Ohio, South Carolina, Tennessee, and Texas. Details 
on AACES methods have been described elsewhere.30 Briefly, rapid case ascertainment at 
cancer registries and hospitals was used to identify cases. Eligible cases included women 
who self-reported AA race, were 20–79 years of age, and were newly diagnosed with 
invasive EOC between December 1, 2010 and December 31, 2015. Controls were identified 
through random digit dialing and frequency matched to cases by 5-year age groups and 
geographic location. Eligible controls included women who self-reported AA race, had at 
least one intact ovary, and did not have a history of EOC. AACES participants completed an 
extensive baseline survey by telephone, including but not limited to questions on 
demographics, reproductive history, exogenous hormone use, personal and family history of 
cancer, medical history, and lifestyle behaviors (e.g., smoking, physical activity). An 
abbreviated form of the questionnaire was offered to women who would have otherwise 
refused to participate in the study. Dietary intake was assessed by the widely used and 
validated31,32 Block 2005 Food Frequency Questionnaire (FFQ). The FFQ was mailed to the 
participant’s residence to obtain self-reported data on the usual consumption (frequency and 
portion size) of 110 foods and beverages during the year before their diagnosis (cases) or the 
year before their interview (controls). All FFQ data were sent to NutritionQuest, formerly 
known as Block Dietary Data Systems, to derive individual nutrient and total energy intake.
Dietary Inflammatory Index
The DII was calculated using the dietary intake data from the FFQ as described in Shivappa, 
et al.14 In brief, the literature was searched from 1950 to 2010 to identify studies examining 
the association between six inflammatory biomarkers (IL-1β, IL-4, IL-6, IL-10, TNF-α, and 
CRP) and specific foods and nutrients. A total of 45 such parameters were identified in the 
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process of conducting this extensive search. Eligible studies were used to define DII scores 
for each food parameter, which also were weighted according to study quality. A database of 
11 dietary datasets from around the world was used to estimate the global mean intake of 
each food parameter. Each subject’s dietary data was linked to the global database and their 
exposure relative to the global mean was expressed as a z-score. The z-score was calculated 
by subtracting the standard global mean from the reported dietary intake and then dividing 
by the global standard deviation. Z-scores were converted to normal percentiles to reduce the 
effect of a positive-skewed distribution. For each food parameter, the literature-derived 
inflammatory effect score for each food parameter was then multiplied by the food 
parameter specific centered percentile for each participant. These values were then summed 
to calculate the overall DII score, where higher scores indicate a more pro-inflammatory 
diet. To control for the effect of total energy intake, the energy-adjusted DII (E-DII) was 
calculated per 1,000 calories of food consumed. We examined the E-DII in two ways, both 
with and without consideration of dietary supplements in addition to food sources of 
nutrients. In total, data was available on 27 food parameters (carbohydrates; protein; fat; 
alcohol; fiber; cholesterol; saturated, monounsaturated, and polyunsaturated fatty acids; 
omega3 and omega6 polyunsaturated fatty acids; trans-fat; niacin; vitamins A, B1, B2, B6, 
B12, C, D, E; iron; magnesium; zinc; selenium; folic acid; beta carotene; and isoflavones). 
The dietary supplements included vitamin A, vitamin C, vitamin D, vitamin E, iron, 
calcium, zinc, beta-carotene, B-1 (thiamin), B-6, B-12, folic acid, copper, selenium, 
riboflavin, magnesium, niacin, omega-3 fatty acids, and omega-6 fatty acids.
The range of E-DII values in our sample were −5.57 to 3.19 and −4.15 to 3.19 for the E-DII 
with and without including dietary supplements, respectively. The E-DII was evaluated 
continuously, where a 1-unit change in the E-DII with and without supplement intake was 
equivalent to about 11% and 14% of its range, respectively, as well as categorically by 
dividing the E-DII scores into quartiles based on its distribution among the controls. For the 
E-DII with supplements, the range of E-DII scores for each quartile are: Quartile 1 (−5.57 to 
−3.64), Quartile 2 (−3.63 to −2.46), Quartile 3 (−2.45 to −0.33), and Quartile 4 (−0.32 to 
3.19); and for the E-DII without supplements, the range of E-DII scores for each quartile 
are: Quartile 1 (−4.15 to −2.18), Quartile 2 (−2.17 to −0.66), Quartile 3 (−0.65 to 1.01), and 
Quartile 4 (1.02 to 3.19).
Statistical Analysis
We used data from AACES participants enrolled in the study as of January 2016 and who 
completed the FFQ (N=1,173). We excluded data from any participants reporting extreme 
values for total energy intake, defined as greater than twice the interquartile range of the log 
energy intake (1 case and 3 controls). Distributions of participant characteristics were 
compared by case-control status using chi-square tests for categorical variables or t-tests for 
continuous variables. We also examined the distribution of selected participant 
characteristics by E-DII quartiles using chi-square tests. Odds ratios (ORs) and 95% 
confidence intervals (CIs) for the association between the E-DII (with supplements and 
without supplements), and odds of ovarian cancer were estimated using multivariable 
logistic regression. To test for linear trends, the median value within each quartile was 
modeled as a continuous variable. Two models with different adjustment sets were 
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examined. Model 1 is adjusted for the study design variables, including age (in years; age at 
diagnosis for cases and age at interview for controls) and study site (Alabama, Georgia and 
Tennessee combined [combined due to geographic similarities and sample size], Illinois and 
Michigan combined [combined due to geographic similarities and sample size], Louisiana, 
New Jersey, North Carolina, Ohio, South Carolina, Texas). Model 2 is additionally adjusted 
for family history of breast or ovarian cancer in a first-degree relative (yes, no), parity (0, 1, 
2, 3 or more live births), duration of OC use (no use, <5 years, 5 or more years), education 
(high school graduate or less, some post high school training, college or graduate degree), 
tubal ligation that occurred 1 year prior to the date of interview for controls and the date of 
diagnosis for cases (yes, no), menopausal status (pre- or peri-menopause, post-menopause), 
and body mass index (BMI; normal weight: <25 kg/m2; overweight: 25–29.9 kg/m2; obese: 
≥30 kg/m2), smoking status (never, former, current smoker), and endometriosis (yes/no). For 
the models examining the E-DII not including supplement intake as part of the calculation, 
the fully adjusted model (Model 2) also was adjusted for any dietary supplement intake in 
the year before diagnosis for cases or year before interview in controls (yes/no), as reported 
in the FFQ. The following potential confounders were evaluated but not included in the 
model because their addition did not change the effect estimate by 10% or more: total energy 
intake, physical activity, arthritis, diabetes, hypertension, high cholesterol, aspirin use, non-
aspirin NSAID use, pelvic inflammatory disease, and body powder use. Ten women were 
missing covariate data and were removed from the analyses (N=1,155). All analyses were 
repeated restricted to the most deadly histologic subtype of EOC, serous ovarian cancer. 
Based on the findings of previous literature on the DII and female malignancies23–25, we 
developed a priori hypotheses to examine whether age (21–50 years, 51–60 years, >60 
years), BMI, smoking status, and menopausal status were effect modifiers of the association 
between the E-DII and ovarian cancer risk. Effect modification was evaluated by adding a 
cross-product term (e.g., BMI × E-DII quartiles) into the regression model and a likelihood 
ratio test was used to compare the models with and without the cross-product term. SAS 9.4 
was used to complete all analyses.
RESULTS
The distribution of participant characteristics for 493 cases and 662 controls are described in 
Table 1. Cases were more likely to have a family history of breast or ovarian cancer in a 
first-degree relative, to be nulliparous, and to have a history of endometriosis; cases were 
less likely to use oral contraceptives, to have a college or graduate degree, to have a tubal 
ligation, to be a current smoker, and to report use of dietary supplements. No statistically 
significant differences in total energy intake were observed for cases and controls. The 
majority of EOC cases were of serous histology (71%).
Overall, the mean and standard deviation (SD) of the E-DII including supplement intake was 
−1.82 ± 2.16; as expected, the mean E-DII score excluding supplement intake was greater or 
more pro-inflammatory (−0.51 ± 1.87) compared to the E-DII score including supplements. 
For both measures of the E-DII, cases, on average, had a more pro-inflammatory diet 
compared to controls (mean ± SD of the E-DII including supplements: cases = −1.70 ± 2.19 
and controls = −1.91 ± 2.13, and for the E-DII not including supplements: cases = −0.43 
± 1.84 and controls = −0.57 ± 1.89). Supplementary Tables 1 and 2 provide the distribution 
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of selected characteristics across E-DII quartiles for the E-DII calculated with and without 
supplement intake among controls. Across both measures of the E-DII, a more pro-
inflammatory diet was observed among women who were younger, less educated, pre- or 
peri-menopausal, current smokers, and who did not engage in any physical activity.
The estimated ORs and 95% CIs for the E-DII and EOC risk are provided in Table 2. When 
evaluating the E-DII including supplement intake continuously, we observed a 10% increase 
in the risk of EOC for every one unit change in E-DII score (OR=1.10, 95% CI=1.03–1.17). 
As the E-DII quartiles increased from more anti-inflammatory to more pro-inflammatory, a 
significant trend in EOC risk was observed (ptrend=0.01). Women in the highest quartile of 
the E-DII had a statistically significant increased risk of EOC in comparison to the lowest 
quartile, ORQ4/Q1 = 1.72, 95% CI=1.18–2.51. For the E-DII not including supplements, the 
associations were weaker and not statistically significant. When the analyses were repeated 
restricted to serous EOC cases versus all controls, the ORs were slightly attenuated but no 
substantial differences in the results were observed (data not shown).
We observed statistically significant effect modification by menopausal status (Table 3) and 
age (Table 4) for the E-DII excluding dietary supplement intake (p<0.05), but not for the E-
DII including dietary supplement intake. Among pre- and peri-menopausal women, no 
associations were observed between the E-DII not including supplements and EOC risk; 
however, among post-menopausal women, the highest, more pro-inflammatory, quartile 
(Quartile 4) was associated with a statistically significant increased risk of EOC (ORQ4/Q1 = 
1.63, 95% CI=1.05–2.54). Similarly, women older than 60 years of age had much higher 
risks of EOC for both E-DII measures in comparison to women aged 60 and younger. An 
increased risk was observed for a one-unit change in the E-DII with and without 
supplements among women older than 60 years of age, OR=1.22; 95% CI=1.09–1.37 and 
OR=1.27; 95% CI=1.11–1.45, respectively. The highest increase in EOC risk was observed 
for women older than 60 years of age and in the fourth, most pro-inflammatory, quartile, 
ORQ4/Q1 = 3.23 (95% CI=1.63–6.40) for the E-DII including supplements and ORQ4/Q1 = 
3.77 (95% CI=1.82–7.77) for the E-DII excluding supplements. No evidence of effect 
modification by BMI or smoking status was observed (data not shown).
DISCUSSION
In a population of AA women in the United States, a more pro-inflammatory diet was 
positively associated with EOC risk. These findings are consistent with the only other study 
examining the DII and EOC risk.25 Although few studies have looked specifically at the 
inflammatory potential of one’s diet in relation to ovarian cancer, individual nutrients and 
dietary patterns that contribute to inflammation have been assessed previously, yet the 
results have been fairly inconsistent.33 Although fruit and vegetable intake is associated with 
lower levels of inflammatory biomarkers12,34, a protective effect of fruit and vegetable 
intake on ovarian cancer risk was observed neither in a pooled analysis of 12 cohort 
studies35 or in the European Prospective Investigation into Cancer and Nutrition (EPIC) 
Study.36 Simple carbohydrates and high-glycemic carbohydrates have pro-inflammatory 
effects12 and an increase in EOC risk has been observed for high glycemic index, especially 
among overweight and obese women.37 Similarly, an increased risk of EOC was observed in 
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the AACES population for women consuming a carbohydrate-rich diet.38 Our findings 
coupled with the previous studies evaluating food-specific effects on EOC risk suggest that a 
diet full of fruits, vegetables, and complex carbohydrates, would result in reductions in 
inflammation and potentially a reduced risk of EOC. It is important to note that a more pro-
inflammatory diet is highly correlated with the Western diet12, which is characterized by 
high intake of red meat and simple carbohydrates, making it difficult to disentangle whether 
the increased risk of EOC is due to the inflammatory potential of these foods or other 
consequences of consumption of the Western diet.
We observed statistically significant effect modification by both menopausal status and age; 
among post-menopausal women and women older than 60 years of age, a more pro-
inflammatory diet was strongly associated with an increased risk of EOC, while no 
association was seen for pre-menopausal women and women 60 years of age and younger. 
Studies in breast23, endometrial24, and ovarian25 cancer observed similar results, where a 
positive association between the DII and cancer risk was present only among post-
menopausal women, albeit not statistically significant. In these three studies, age was not 
assessed as a potential effect modifier. Age and menopausal status are highly correlated with 
one another, and in this study, the age group where we see the strongest association, women 
older than 60 years, are a subset of post-menopausal women. As the relationship observed in 
older women is stronger than that in post-menopausal women and the results were 
essentially null in the other age subset of post-menopausal women (ages 51–60 years), age 
seems to be driving the effect modification present in this study, not menopausal status. It 
also is important to note that we found no evidence of effect modification of E-DII scores by 
BMI or smoking status. Both BMI and tobacco are known to work through inflammation-
related mechanisms39,40, yet there is no apparent modification of the effect of diet-
associated inflammation by either of these two factors in this study.
It is unclear as to why a stronger association between the E-DII and EOC risk was observed 
mainly among older women. It is possible that these findings are consistent with the 
observation that environmental or lifestyle factors, such as the E-DII, may be stronger 
determinants of hormonally sensitive cancers diagnosed in older women compared to 
cancers diagnosed in younger women, which are more genetically determined.41 In addition, 
our findings may reflect a cumulative effect of consumption of pro-inflammatory foods over 
the life-course. Another explanation could also be related to variations in insulin with aging 
since insulin resistance is associated with both older ages42 and increases in inflammation.43 
In fact, using diabetes as a proxy for insulin resistance, we observed a higher prevalence of 
diabetes among women older than 60 years of age in the AACES population compared to 
those 60 years old and younger (48% vs. 18%, respectively). Insulin resistance also 
increases with obesity, which is highly prevalent in AACES (57%).
In contrast to much of the published DII literature, we incorporated dietary supplement 
intake as part of the E-DII calculation and as a potential confounder for the association 
between the E-DII without supplements and ovarian cancer risk. Although dietary 
supplements are not classified as a typical dietary food item, they are important contributors 
to nutrient intake as they often contain nutrient doses which surpass those available from 
food sources. Moreover, approximately half of the U.S. population uses dietary supplements, 
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with a higher prevalence of supplement use among women and older individuals.44 
Supplement intake has been linked to lower levels of inflammation45 and several 
studies46–50 have observed protective effects of supplement use on ovarian cancer risk. In 
contrast, high doses of some supplements have been shown to increase cancer risk.51 As 
supplement intake is associated with both inflammation and cancer risk, not including this 
factor could lead to residual confounding. In fact, in this study, we observed significant 
positive confounding (approximately a 40% change in the OR) when adjusting for 
supplement intake in the models examining the E-DII without supplements and EOC risk. 
With such a substantial effect on our results, it is important for future studies to evaluate 
dietary supplements either as a contributor to the E-DII or to evaluate supplements as a 
potential confounder.
A major strength of this study is the utilization of the AACES population, which includes 
the largest number of AA women with EOC to date and is uniquely positioned to examine 
race-specific effects in ovarian cancer. Another strength is using the E-DII to assess the 
inflammatory potential of one’s diet because this approach allows simultaneous assessment 
of both pro- and anti-inflammatory factors instead of looking at each inflammatory dietary 
component individually. Despite these strengths, there are several limitations. Due to the 
case-control study design, there is a possibility of recall bias. However, given that the 
influence of dietary factors on ovarian cancer risk is still relatively unknown, it is unlikely 
that AACES participants were aware of hypotheses related to diet and EOC. Yet, there is a 
general belief that diet is an important determinant of health and well-being. If any 
misclassification of exposure occurred, it is unlikely that cases recalled their dietary intake 
differently compared to controls, which would bias the results toward the null. Given that the 
FFQ reflects usual dietary intake a year prior to diagnosis among the cases, there is a 
possibility that symptoms of an undiagnosed ovarian cancer (e.g., pelvic or back pain, 
fatigue, loss of appetite) may have spurred changes in diet during the time period captured 
by the FFQ. Another limitation is that only 27 of the 45 food parameters identified in the 
original literature search were available to calculate the E-DII in this study. We were also 
unable to validate the E-DII scores with inflammatory biomarkers in the AACES population; 
however, a recent study18 validated the E-DII in an African American population by 
correlating the E-DII scores and CRP concentrations. The literature search for the DII has 
not been updated since 2010; however, with each literature update, the DII scores have 
remained relatively stable over time.14 Although AACES is a relatively large sample overall, 
we had limited power in the stratified analyses, resulting in imprecise estimates with wide 
confidence intervals. Additionally, we were unable to perform stratified analyses by 
histology due to the small number of cases diagnosed with non-serous EOC and could only 
repeat the overall analyses restricted to the most common histology, serous EOC.
In summary, a more pro-inflammatory diet was associated with an increased risk of EOC in 
AA women, especially among women older than 60 years of age. Given that only one other 
study has examined the relationship between the inflammatory potential of one’s diet and 
ovarian cancer, it is important to confirm these findings, especially among racially diverse 
populations that may have varying dietary habits. With very few modifiable risk factors for 
ovarian cancer currently known, our results suggest that modifying dietary intake to include 
fewer inflammatory foods may contribute to ovarian cancer prevention.
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Although ovarian carcinogenesis has been linked to inflammation, the impact of an 
inflammatory diet on ovarian cancer risk is understudied. We examined the association 
between the inflammatory potential of one’s diet, as assessed by a novel literature-
derived tool, the dietary inflammatory index (DII), and ovarian cancer risk among 
African American women. A more pro-inflammatory diet was associated with an 
increased risk of ovarian cancer, especially among women older than 60 years of age.
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Table 1





n (%) or Mean (SD) n (%) or Mean (SD) p-value
Age at Diagnosis or Interview
  21–50 years 122 (25) 198 (30) 0.007
  51–60 years 177 (36) 261 (39)
  >60 years 194 (39) 203 (31)
Total Energy Intake
  Kilocalories 1763.8 (1187.0) 1720.4 (1112.8) 0.52
Education
  HS or less 214 (44) 244 (37) 0.08
  Some post HS training 125 (25) 191 (29)
  College or graduate degree 154 (31) 227 (34)
BMI (kg/m2)a
  <25 75 (15) 125 (19) 0.26
  25–29.9 129 (26) 163 (25)
  30+ 289 (59) 374 (56)
Family History of Breast or Ovarian Cancer
  No 364 (74) 542 (82) 0.001
  Yes 129 (26) 120 (18)
Menopausal Status
  Pre/Peri-menopause 138 (28) 199 (30) 0.44
  Post-menopause 355 (72) 463 (70)
Parity
  Nulliparous 95 (19) 84 (13) 0.01
  1 98 (20) 121 (18)
  2 119 (24) 180 (27)
  3+ 181 (37) 277 (42)
Duration of OC Use
  Never 163 (33) 154 (23) <0.001
  <5 years 191 (39) 282 (43)
  5+ years 139 (28) 226 (34)
Tubal Ligation
  No 324 (66) 389 (59) 0.02
  Yes 169 (34) 273 (41)
Smoking Status
  Never smoker 273 (55) 381 (57) <0.001
  Former smoker 167 (34) 150 (23)
  Current smoker 53 (11) 131 (20)
Endometriosis


















n (%) or Mean (SD) n (%) or Mean (SD) p-value
  No 437 (89) 631 (95) <0.001
  Yes 56 (11) 31 (5)
Any Dietary Supplement Use (Past Year)
  No 143 (29) 142 (21) 0.003
  Yes 350 (71) 520 (79)
Histology
  Serous 333 (71)
  Mucinous 24 (5)
  Endometrioid 62 (13)
  Clear cell 12 (3)
  Mixed 14 (3)
  Other Epithelial 23 (5)
  Missing 25
BMI: body mass index; HS: high school; OC: oral contraceptives
a
BMI 1 year before diagnosis date for cases and interview date for controls.
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Table 2
Estimated ORs and 95% CIs for the association between energy-adjusted DII and ovarian cancer risk 
(N=1,155)
Cases Controls Model 1a Model 2b
Quartile of Energy-adjusted DII n (%) n (%) OR (95% CI) OR (95% CI)
E-DII including supplements
  Quartile 1 108 (22) 167 (25) 1.00 (Referent) 1.00 (Referent)
  Quartile 2 125 (25) 164 (25) 1.22 (0.86–1.73) 1.40 (0.97–2.01)
  Quartile 3 123 (25) 166 (25) 1.20 (0.85–1.69) 1.33 (0.92–1.92)
  Quartile 4 137 (28) 165 (25) 1.52 (1.07–2.14) 1.72 (1.18–2.51)
    Ptrend 0.03 0.01
  Per 1 unit of E-DII 1.08 (1.02–1.14) 1.10 (1.03–1.17)
E-DII excluding supplementsc
  Quartile 1 117 (24) 167 (25) 1.00 (Referent) 1.00 (Referent)
  Quartile 2 113 (23) 166 (25) 0.95 (0.67–1.35) 0.94 (0.65–1.34)
  Quartile 3 129 (26) 164 (25) 1.15 (0.82–1.62) 1.16 (0.80–1.68)
  Quartile 4 134 (27) 165 (25) 1.37 (0.97–1.93) 1.35 (0.93–1.97)
    Ptrend 0.04 0.06
  Per 1 unit of E-DII 1.08 (1.01–1.16) 1.08 (1.00–1.16)
OR: odds ratio; CI: confidence interval; E-DII: energy-adjusted dietary inflammatory index; OC: oral contraceptives; BMI: body mass index
a
Model 1 is adjusted for the study design variables, age and study site.
b
Model 2 is adjusted for the variables in Model 1 as well as family history of breast or ovarian cancer in a first degree relative, parity, OC use, 
education, BMI, tubal ligation, menopausal status, smoking status, and endometriosis.
c
Model 2 is also adjusted for any use of dietary supplements in the past year.
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Table 3
Estimated ORs and 95% CIs for the association between the energy-adjusted DII and ovarian cancer risk 
stratified by menopausal status (N=1,155)
Menopausal Status
Pre- and Peri-menopausal Women Post-menopausal Women
Quartile of Energy-adjusted DII
No. of
cases/controls ORa (95% CI)
No. of
cases/controls ORa (95% CI)
E-DII including supplements
  Quartile 1 25/39 1.00 (Referent) 83/128 1.00 (Referent)
  Quartile 2 36/42 2.35 (1.05–5.26) 89/122 1.23 (0.81–1.87)
  Quartile 3 33/47 1.82 (0.80–4.16) 90/119 1.29 (0.85–1.97)
  Quartile 4 44/71 2.14 (0.96–4.76) 93/94 1.84 (1.18–2.87)
    Ptrend 0.24 0.008
  Per 1 unit of E-DII 1.09 (0.96–1.24) 1.13 (1.05–1.21)
E-DII excluding supplementsb
  Quartile 1 27/36 1.00 (Referent) 90/131 1.00 (Referent)
  Quartile 2 29/48 0.89 (0.40–1.99) 84/118 0.97 (0.64–1.46)
  Quartile 3 39/39 2.14 (0.94–4.86) 90/125 1.01 (0.66–1.55)
  Quartile 4 43/76 1.17 (0.53–2.58) 91/89 1.63 (1.05–2.54)
    Ptrend 0.39 0.04
  Per 1 unit of E-DII 1.10 (0.94–1.28) 1.10 (1.01–1.20)
OR: odds ratio; CI: confidence interval; E-DII: energy-adjusted dietary inflammatory index; OC: oral contraceptives; BMI: body mass index
a
ORs are adjusted for age, study site, family history of breast or ovarian cancer in a first degree relative, parity, OC use, education, BMI, tubal 
ligation, smoking status, and endometriosis.
b
ORs additionally adjusted for any use of dietary supplements in the past year.
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